

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10502145	
	Filing Date		2005-05-05	
	First Named Inventor	MACKAY, CHARLES REAY		
	Art Unit	1644		
	Examiner Name	VANDERVEGT, FRANCOIS P		
Attorney Docket Number		RICE-032		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10502145
Filing Date	2005-05-05
First Named Inventor	MACKAY, CHARLES REAY
Art Unit	1644
Examiner Name	VANDERVEGT, FRANCOIS P
Attorney Docket Number	RICE-032

1	CAIN ET AL., Mapping the Ligand-Binding Site on the C5a Receptor: Arginine74 of C5a Contacts Aspartate282 of the C5a Receptor. Biochemistry 2001;40:14047-52.	<input type="checkbox"/>
2	CAIN ET AL., Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor. Biochem. Pharm. 2001;61:1571-9.	<input type="checkbox"/>
3	CRASS ET AL., Receptor Activation by Human C5a des Arg74 but Not Intact C5a Is Dependent on an Interaction between Glu199 of the Receptor and Lys68 of the Ligand. Biochemistry 1999;38:9712-17.	<input type="checkbox"/>
4	DEMARTINO ET AL., Arginine 206 of the C5a Receptor Is Critical for Ligand Recognition and Receptor Activation by C-terminal Hexapeptide Analogs. J. Biol. Chem. 1995;270(27):15966-9.	<input type="checkbox"/>
5	GERBER ET AL., An Activation Switch in the Ligand Binding Pocket of the C5a Receptor. J. Biol. Chem. 2001;276:3394-3400.	<input type="checkbox"/>
6	LEE ET AL., Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nature Biotechnology 2006;24(10):1279-84.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.